The aim of this study was to evaluate the effect of ganciclovir on human herpesvirus-6 (HHV)-6. Forty allogeneic stem cell transplant recipients were prospectively studied by repeated sampling of the saliva. The saliva samples were assayed for HHV-6 by quantitative polymerase chain reaction. HHV-6 was detected in 33 patients. Ganciclovir was given as preemptive therapy for cytomegalovirus infection during 15 episodes that were compared to 18 episodes without any concomitant antiviral therapy. The mean HHV-6 load decreased 0.49 (s.e. 0.31) log 10 /week in patients receiving ganciclovir whereas it increased 0.15 (s.e. 0.17) log 10 /week in episodes without antiviral therapy (P ¼ 0.04). We conclude that ganciclovir can decrease the HHV-6 viral load in saliva.
Introduction
Human herpesvirus-6 (HHV-6) is a b-herpesvirus closely related to cytomegalovirus (CMV) and HHV-7. HHV-6 exists in two subtypes that differ in 4-8% of the DNA. Subtype B is the cause of exanthem subitum in childhood.
It is unclear what if any disease that is caused by the primary infection of subtype A. HHV-6 has a propensity for the CNS and several studies have shown that HHV-6 is an important cause of encephalitis in transplant recipients. [1] [2] [3] [4] [5] HHV-6 has further been associated with skin rashes, interstitial pneumonia, encephalitis, hepatitis and bone marrow suppression after stem cell transplant (SCT). 3, [6] [7] [8] [9] [10] There has been no controlled study of antiviral therapy in patients with HHV-6 infections. Salivary gland epithelium supports HHV-6 replication and infectious HHV-6 is frequently detectable in saliva. We therefore wanted to evaluate the antiviral effectiveness by measuring the HHV-6 viral load in saliva of SCT recipients receiving preemptive ganciclovir therapy for CMV infections.
Patients and methods

Patients
Forty allogeneic SCT recipients were included in the study. The transplant procedure has been described in detail elsewhere.
11 Saliva samples were collected through mouth rinses with water before, at 2, 4 and 12 weeks after SCT, before the start of antiviral therapy and weekly during the therapy. The ethical committee at the Karolinska Institute approved the study. All participants gave written consent to participation after having received oral and written information about the procedures.
HHV-6 PCR assay DNA was extracted by a BioRobot M48 (QIAGENinstruments AG). The viral load was determined by a real-time polymerase chain reaction (PCR). The selected primers (forward: 5 0 gaa tta tat gtt gat tgc tgt gct ttg 3 0 , reverse: 5 0 ccg ccg ggt agc aca a 3 0 ) and minor groove binding probe (5 0 6-carboxy-fluorescein-tgt atc tga aaa gtt aga gtt ggat 3 0 ) were amplifying the 10R gene and the sequences were selected with the primer express software (ABI). For each well, 5 ml of the extracted sample was mixed with 12.5 ml Mastermix (2 Â , ABI) probe to give a final concentration of 300 nm, forward and reverse primers to give final concentrations of 300 and 900 nm, respectively. Distilled water was added to a final volume of 25 ml. The samples were analyzed in triplicates, including one inhibition control to which 0.5 ml positive control containing 15 viral copies was added to control for inhibitory substances in the samples giving a false-negative result. The viral load was calculated in comparison to an external standard in an ABI PRISM 7900H. 12 The mean value of the duplicates was used in the calculations. One positive sample from each of 18 patients was subtyped by qualitative type-specific PCR.
Preemptive antiviral therapy Antiviral therapy was given against CMV as indicated based on a positive PCR for CMV DNA.
14 Ganciclovir 5 mg/kg i.v. twice daily was the primary therapeutic option.
Definitions
An episode of 'HHV-6 excretion with ganciclovir therapy' was defined as 14 days of antiviral therapy in a patient with HHV-6 shedding before the initiation of ganciclovir therapy and during which at least two saliva samples were collected. An 'untreated episode' of HHV-6 excretion was defined as at least a 2-week period, during which at least two saliva samples, of which at least one must be HHV-6 positive, were collected and no antiviral therapy was given. At least 2 weeks had to pass between the end of ganciclovir treatment and the beginning of a new episode either treated or untreated. The change in the viral load was calculated by subtracting the viral load of the last sample from the viral load in the first sample of the episode divided by the number of weeks of observation. A viral load decrease was defined as at least a 50% reduction in the viral load during the episode.
Statistics
Mann-Whitney U-test was used for comparing the change in viral loads between treated and non-treated episodes. Fisher's exact test was used to compare the number of episodes with HHV-6 viral load decrease.
Results
Detection of HHV-6 in saliva Two hundred and fifty-nine saliva samples were collected from the 40 patients. The median number of samples per patient was seven. Thirty-three of the 40 patients had HHV-6 detected at least once in the saliva. A total of 41 HHV-6 shedding episodes from 30 of the patients were identified. In the other three patients, a follow-up sample after the HHV-6-positive sample was either not taken or was taken too long after the positive sample. Overall, 114 of the 259 (44.0%) samples were positive for HHV-6 DNA and the median number of positive samples per patient was two. The strains from 18 samples were subtyped. Sixteen strains were subtype B whereas two strains could not be typed. No symptoms attributable to HHV-6 were seen.
Antiviral therapy
Ganciclovir was given during 15 of the HHV-6 shedding episodes, 18 episodes were untreated and during eight episodes another antiviral drug was given (foscarnet in three episodes; cidofovir in two and valacyclovir in three episodes). These latter eight episodes were not further analyzed owing to the low number for each antiviral drug.
Fifteen ganciclovir treatment episodes from 13 patients were analyzed. The mean viral load at the start of antiviral therapy was 2.95 log 10 copies/ml saliva and had decreased after therapy to a mean viral load of 1.86 log 10 copies/ml saliva ( Figure 1) ; a 12-fold decrease. The saliva viral load decreased a mean of 0.49 (s.e. 0.31) log 10 copies per week during treatment. When analyzing individual episodes, the saliva viral load decreased in 12/15 (80%) patients during ganciclovir therapy.
HHV-6 saliva levels in absence of antiviral therapy
Eighteen untreated episodes of HHV-6 secretion in saliva were documented. The mean viral load at was 2.6 and 3.05 log 10 copies/ml in the beginning and the end of the episode, respectively (Figure 1 ). The mean viral load increased with 0.15 (s.e. 0.17) log 10 /week during these episodes (P ¼ 0.04 compared to ganciclovir-treated episodes). When analyzing individual episodes, the saliva viral load decreased in 7/18 (39%) episodes (P ¼ 0.03 compared to ganciclovir-treated episodes).
The untreated episodes occurred slightly earlier (mean 21 days s.d.724.6) compared to the ganciclovir-treated episodes (mean 41 days; s.d.727.5; P ¼ 0.07).
Discussion
Only limited data exist regarding the efficacy of antiviral therapy on HHV-6. We chose to study saliva for a 'proof of concept' study as HHV-6 excretion in saliva is very common and in order to get a large enough sample to allow comparisons between ganciclovir treated and nontreated patients. It could be argued that the sampling procedure was not standardized and that variations in the procedure might explain the results. This is of course possible but we tried to as far as possible standardize the procedure using similar volumes of mouth rinsing fluid. Furthermore, in our opinion, the same risk for variation in the sampling procedures existed in patients treated with ganciclovir as in non-treated patients. We choose saliva as our study material as HHV-6 is more frequently found in saliva than in plasma and it would therefore give us a better chance of an effect of antiviral therapy than if we would have used plasma or whole blood. It has also been shown Effectiveness of ganciclovir against HHV-6 P Ljungman et al previously that HHV-6 is detected in plasma early after transplant at a time when CMV is more uncommonly detected.
We did in fact also analyze plasma and could only document two episodes timed so that the effect of GCV on HHV-6 could have been studied. Our results show that preemptively given ganciclovir were able to reduce the saliva viral load in 80% of the episodes. Furthermore, the mean HHV-6 viral load decreased in the ganciclovir-treated episodes whereas it increased in the non-treated episodes strongly supporting an antiviral effect of ganciclovir on HHV-6. Most of our HHV-6 strains were subtype B. In vitro studies have given partly diverging results for the two subtypes. Long et al. 15 showed a similar effectiveness of ganciclovir, cidofovir and foscarnet against the HHV-6 subtype A but poor efficacy of foscarnet against subtype B. De Clercq et al. 16 showed in contrast similar efficacy of ganciclovir, foscarnet and cidofovir on both HHV-6 subtypes. In vivo studies have suggested efficacy of both ganciclovir and foscarnet in treatment of HHV-6 encephalitis although these data come from anecdotal reports and small patient series. 9, 17 Tokimasa et al. 18 reported a lower risk for HHV-6 reactivation among patients receiving ganciclovir prophylaxis against CMV. Would other antiviral agents have been similarly or more effective? We have data on a few episodes when foscarnet, cidofovir or valacyclovir was given but the number of episodes is too low to allow any conclusions.
Thus, ganciclovir may inhibit HHV-6 replication in the salivary glands. The methodology described might be used for further assessments of the efficacy of ganciclovir and that of other antiviral agents against HHV-6.
